Therapeutic Outcomes and Prognostic Factors in Childhood Absence Epilepsy
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background and Purpose Childhood absence epilepsy (CAE) is one of the most common types of pediatric epilepsy. It is generally treated with ethosuximide (ESM), valproic acid (VPA), or lamotrigine (LTG), but the efficacy and adverse effects of these drugs remain controversial. This study compared initial therapy treatment outcomes, including VPA-LTG combination, and assessed clinical factors that may predict treatment response and prognosis. Methods Sixty-seven patients with typical CAE were retrospectively enrolled at the Korea University Medical Center. We reviewed patients’ clinical characteristics, including age of seizure onset, seizure-free interval, duration of seizure-free period, freedom from treatment failure, breakthrough seizures frequency, and electroencephalogram (EEG) findings. Results The age at seizure onset was 7.9±2.7 years (mean±SD), and follow-up duration was 4.4±3.7 years. Initially, 22 children were treated with ESM (32.8%), 23 with VPA (34.3%), 14 with LTG (20.9%), and 8 with VPA-LTG combination (11.9%). After 48 months of therapy, the rate of freedom from treatment failure was significantly higher for the VPA-LTG combination therapy than in the three monotherapy groups (p=0.012). The treatment dose administrated in the VPA-LTG combination group was less than that in the VPA and LTG monotherapy groups. The shorter interval to loss of 3-Hz spike-and-wave complexes and the presence of occipital intermittent rhythmic delta activity on EEG were significant factors predicting good treatment response. Conclusions This study showed that low-dose VPA-LTG combination therapy has a good efficacy and fewer side effects than other treatments, and it should thus be considered as a first-line therapy in absence epilepsy.
Abstract
Background and Purpose Childhood absence epilepsy (CAE) is one of the most common types of pediatric epilepsy. It is generally treated with ethosuximide (ESM), valproic acid (VPA), or lamotrigine (LTG), but the efficacy and adverse effects of these drugs remain controversial. This study compared initial therapy treatment outcomes, including VPA-LTG combination, and assessed clinical factors that may predict treatment response and prognosis. Methods Sixty-seven patients with typical CAE were retrospectively enrolled at the Korea University Medical Center. We reviewed patients’ clinical characteristics, including age of seizure onset, seizure-free interval, duration of seizure-free period, freedom from treatment failure, breakthrough seizures frequency, and electroencephalogram (EEG) findings. Results The age at seizure onset was 7.9±2.7 years (mean±SD), and follow-up duration was 4.4±3.7 years. Initially, 22 children were treated with ESM (32.8%), 23 with VPA (34.3%), 14 with LTG (20.9%), and 8 with VPA-LTG combination (11.9%). After 48 months of therapy, the rate of freedom from treatment failure was significantly higher for the VPA-LTG combination therapy than in the three monotherapy groups (p=0.012). The treatment dose administrated in the VPA-LTG combination group was less than that in the VPA and LTG monotherapy groups. The shorter interval to loss of 3-Hz spike-and-wave complexes and the presence of occipital intermittent rhythmic delta activity on EEG were significant factors predicting good treatment response. Conclusions This study showed that low-dose VPA-LTG combination therapy has a good efficacy and fewer side effects than other treatments, and it should thus be considered as a first-line therapy in absence epilepsy.
참고문헌 (24)
- Panayiotopoulos CP, "Treatment of typical absence seizures and related epileptic syndromes", Paediatr Drugs, 3, pp.379~403 (2001)
- Jallon P, "Epidemiology of idiopathic generalized epilepsies", Epilepsia, 46(Suppl 9), pp.10~14 (2005)
- Hirsch E, "Epileptic syndromes in infancy, childhood and adolescence", pp.315~335 (2005), John Libbey Eurotext
- Trinka E, "Long-term prognosis for childhood and juvenile absence epilepsy", J Neurol, 251, pp.1235~1241 (2004)
- Posner EB, "Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents", Cochrane Database Syst Rev, 4, pp.CD003032~ (2005)
- 이주영, "소아청소년기 결신 발작에서 일차 약제로서 Lamotrigine의 치료 효용에 관한 연구", 대한소아신경학회지, 19(2), pp.141~148 (2011), 대한소아신경학회
- Coppola G, "Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study", Epilepsia, 45, pp.1049~1053 (2004)
- Glauser TA, "Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy", N Engl J Med, 362, pp.790~799 (2010)
- Coppola G, "Lamotrigine as first-line drug in childhood absence epilepsy: a clinical and neurophysiological study", Brain Dev, 26, pp.26~29 (2004)
- Hughes JR, "Absence seizures: a review of recent reports with new concepts", Epilepsy Behav, 15, pp.404~412 (2009)
- Grosso S, "Childhood absence epilepsy: evolution and prognostic factors", Epilepsia, 46, pp.1796~1801 (2005)
- Wirrell EC, "Natural history of absence epilepsy in children", Can J Neurol Sci, 30, pp.184~188 (2003)
- Matricardi S, "Current advances in childhood absence epilepsy", Pediatr Neurol, 50, pp.205~212 (2014)
- Mandelbaum DE, "Impact of antiepileptic drugs on cognition, behavior, and motor skills in children with newonset, idiopathic epilepsy", Epilepsy Behav, 16, pp.341~344 (2009)
- Guilhoto LM, "Occipital intermittent rhythmic delta activity in absence epilepsy", Arq Neuropsiquiatr, 64(2A), pp.193~197 (2006)
- Dlugos D, "Pretreatment EEG in childhood absence epilepsy: associations with attention and treatment outcome", Neurology, 81, pp.150~156 (2013)
- Li Q, "EEG-fMRI study on the interictal and ictal generalized spike-wave discharges in patients with childhood absence epilepsy", Epilepsy Res, 87, pp.160~168 (2009)
- Wirrell EC, "Long-term prognosis of typical childhood absence epilepsy: remission or progression to juvenile myoclonic epilepsy", Neurology, 47, pp.912~918 (1996)
- Posner EB, "A systematic review of treatment of typical absence seizures in children and adolescents with ethosuximide, sodium valproate or lamotrigine", Seizure, 14, pp.117~122 (2005)
- Wheless JW, "Acute management of seizures in the syndromes of idiopathic generalized epilepsies", Epilepsia, 44(Suppl 2), pp.22~26 (2003)
- Glauser TA, "Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months", Epilepsia, 54, pp.141~155 (2013)
- Brodie MJ, "Combining antiepileptic drugs--rational polytherapy?", Seizure, 20, pp.369~375 (2011)
- Pisani F, "The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction", Epilepsia, 40, pp.1141~1146 (1999)
- Moeller JJ, "Lamotrigine-valproic acid combination therapy for medically refractory epilepsy", Epilepsia, 50, pp.475~479 (2009)